TH73873A - Short-form c-Maf genetic copy factor antagonist for the treatment of glaucoma. - Google Patents

Abstract

DC60 (24/01/48) The short form of the transcript factor c-Maf has been more upregulated in steroid-treated and/or beta-2-treated connective tissue (CT) cells and is at higher levels between glaucoma and normal CT cells and between glaucoma and normal optic nerve head tissue. The expression of the short form of c-Maf under these conditions indicates an uncertain role or sensory receptor role for the factor in the pathogenesis of early open-angle glaucoma, and due to steroids, antagonism of the expression and/or activity of the short form of c-Maf in CT or other ocular tissues is to inhibit or alleviate the pathogenesis of glaucoma. Various antagonists, including two cyclin-dependent kinase inhibitors, In normal ocular lateral network and glaucoma with normal optic nerve head tissue, the expression of the c-Maf gene factor under these various conditions indicates an uncertain role or sensory receptor role for this factor in the pathogenesis of early open-angle glaucoma, and therefore, steroid antagonism, inhibition of the expression and/or activity of the short c-Maf gene copy in the ocular lateral network or other ocular tissues is intended to inhibit or alleviate the pathogenesis of glaucoma. Various antagonists, including two cyclin-dependent kinase inhibitors, are involved.

Claims (13)

1. The use of a drug preparation containing a short-acting c-Maf copy factor antagonist and an acceptable carrier in effective doses for the treatment of early-stage open-angle glaucoma or steroid-induced glaucoma in experimental animals. 2. Use under claim 1, where the drug is used for the treatment of early-stage open-angle glaucoma. 3. Use under claim 1, where the drug is used to treat steroid-induced glaucoma. 4. Use under Claim 1 where the experimental animals are at risk of developing early-stage open-angle glaucoma or steroid-induced glaucoma. 5. Use under Claim 1 where experimental animals exhibit symptoms of early-stage open-angle glaucoma or steroid-induced glaucoma. 6. An application under Claim 1 where an anti-replication of the short c-Maf copy factor interferes with the replication of the c-Maf gene. 7. Applications under Claim 1 where the antibody of the aforementioned short c-Maf copy factor contains an analogurine that inhibits the cyclin-dependent kinase cdk2. 8. Uses under claim 7 where the anti-inflammatory agent consists of pervalanol A, pervalanol B, amino-pervalanol, olomusin, N9-isopropylolomusin, roscovitine, methoxy-roscovitine, a mixture of these compounds or salts of these compounds. 9. Use under claim 7 where the antibiotic contains pervalanol A, pervalanol B, a mixture of these compounds or salts of these compounds. 10. Use under claim 7 where the anti-inflammatory agent contains pervalanol A. 11. Uses under Claim 1 where the anticoagulant of the aforementioned short c-Maf transcription factor is a cyclin-dependent kinase cdk2-selected from a group consisting of indirubin, oxindole, indenopyrazole, pyridopyrimidine, anilinoquinazoline, aminothiazole, flavopyridol, storoseporine, pollone, hymenialdyzine, a mixture of these compounds or salts of these compounds. 12. Uses under claim 1 where the drug is prepared for injection into the eye, for implantation of slow-release devices, or for topical, oral, or inhaled use. 13. Use under claim 1 where the drug is prepared for topical use.